Brenipatide

Brenipatide (Eli Lilly development code LY3537031) is an investigational dual GIP/GLP-1 receptor co-agonist, the same receptor pair targeted by tirzepatide (Mounjaro, Zepbound), engineered for once-monthly subcutaneous dosing rather than the weekly schedule used by tirzepatide and semaglutide [10][11]. Lilly has not formally disclosed the mechanism in its primary pipeline communications, so GIP/GLP-1 is the characterization from secondary sources consistent with Lilly's incretin platform [6][7][10]. It is now in Phase 3 for major depressive disorder (MDD) relapse prevention (NCT07412756, n=1,000) [1]. The MDD trial is one of five active brenipatide studies spanning psychiatric and substance use indications: MDD, schizophrenia-associated weight, smoking cessation, alcohol use disorder, and opioid use disorder [1][2][3][4][5]. That portfolio breadth telegraphs Lilly's hypothesis: an incretin acting on reward circuitry, satiety signaling, and (via GIP) hippocampal pathways may move endpoints in CNS conditions where current pharmacotherapy is mediocre. If brenipatide hits in any of these, it would extend the GIP/GLP-1 franchise beyond metabolic disease and open a psychiatric category that has stalled commercially since the SSRIs. The MDD program is the most ambitious bet of the five and the most likely to disappoint, given the field's record with novel mood mechanisms. The smoking cessation and AUD trials are the cleaner mechanistic bets and will read first.

Phase 3 in MDD, currently recruiting [1]. Brenipatide is a novel compound with no approvals anywhere. No FDA breakthrough therapy, fast track, or orphan drug designations are listed for the MDD trial in the public registry. Eli Lilly disclosed brenipatide in pipeline tables in its 2025 and 2026 10-K filings but did not publicly specify the mechanism class, target, or chemical scaffold; the GIP/GLP-1 co-agonist characterization comes from secondary registries and trade press [6][7][10][11]. With n=1,000 and a time-to-relapse primary endpoint, the trial needs both a follow-up window long enough to accrue events (typically 9 to 12 months per patient) and adequate enrollment pace. A top-line MDD readout is not realistic before late 2027 at earliest, and 2028 is more likely given recruitment is still ongoing. Four other Phase 2/3 brenipatide trials will read out first and set the prior on the MDD program: smoking cessation (NCT07223840, Phase 2, n=222), schizophrenia-associated weight (NCT07410507, Phase 2, n=450), alcohol use disorder (NCT07219966, Phase 3, n=1,100), and opioid use disorder (NCT07420283, Phase 2, n=465) [2][3][4][5]. The smoking cessation and AUD reads are the earliest meaningful data drops; if the smoking cessation study completed enrollment in early 2026, top-line is plausible Q1 to Q2 2027.

GLP-1 (glucagon-like peptide-1) is a gut hormone released after meals that signals satiety to the brain and slows glucose absorption. Drugs like semaglutide bind the GLP-1 receptor on pancreatic and brain cells to drive weight loss and lower blood sugar. Less appreciated: GLP-1 receptors also sit in reward and mood circuits (nucleus accumbens, ventral tegmental area, prefrontal cortex), and activating them dampens craving in animal models of alcohol, nicotine, and opioid seeking. GIP (gastric inhibitory polypeptide, also called glucose-dependent insulinotropic polypeptide) is a separate gut hormone released from intestinal K cells after meals. It potentiates insulin secretion in a glucose-dependent way and, relevant to CNS indications, GIP receptors are expressed in the hippocampus and other brain regions with putative roles in memory, food reward, and neuroinflammation. The CNS rationale for GIP co-agonism on top of GLP-1 is that GIP receptors add a complementary signal in hippocampal and reward circuits that GLP-1 alone does not engage. The metabolic rationale, established by tirzepatide, is that GIP co-agonism improves both weight loss and GI tolerability versus GLP-1 alone. The case that this mechanism helps depression rests on three observations. First, semaglutide users in retrospective EHR analyses show reduced incidence and recurrence of suicidal ideation versus matched controls on non-incretin anti-obesity or anti-diabetes drugs [8]. (Note: this is a safety signal, not a mood efficacy signal; a cleanly attributable mood/anxiety benefit has not been established in prospective trials.) Second, obese patients with depression who lose significant weight on incretin drugs see depression scores improve, though it is hard to separate weight effects from direct neural effects. Third, a subset of treatment-resistant depression looks inflammatory, and both GLP-1 and GIP signaling modulate inflammation. None of this is clean genetic validation. There is no GWAS hit (genome-wide association study, the method that screens hundreds of thousands of genetic variants for statistical association with a disease) linking GLP-1 or GIP receptor variants to MDD outcomes. The addiction indications (smoking, AUD, OUD) carry the strongest mechanistic prior because incretin drugs reducing addictive consumption is a real signal in observational data. MDD is more of a stretch, and the trial design admits this by going after maintenance rather than acute treatment.

NCT07412756 randomizes 1,000 adults with MDD currently in remission on standard antidepressant therapy to brenipatide plus standard of care versus placebo plus standard of care [1]. The primary endpoint is time from randomization to relapse, defined by predefined symptom criteria. Relapse is typically declared by crossing a threshold on a clinician-rated symptom scale such as MADRS (Montgomery-Asberg Depression Rating Scale) or HAM-D (Hamilton Depression Rating Scale), where higher scores mean more severe depression, combined with clinician-judged symptomatic worsening. This is a relapse-prevention design, not an acute treatment design. Lilly is positioning brenipatide as a maintenance add-on, not a monotherapy challenger to SSRIs. That design choice matters. Acute MDD trials are notoriously plagued by placebo response (40 to 50% response on placebo alone), which has killed many programs. Relapse prevention dodges that problem because the endpoint is a discrete event accrued over time rather than a symptom score change. With n=1,000 and a 9 to 12 month follow-up window, this is appropriately sized for a placebo-arm relapse rate in the 25 to 35% range. The biggest weakness: no biomarker stratification. Lilly is not enriching for inflammatory depression, metabolically driven depression, or any defined endophenotype (a biologically definable patient subgroup within a clinically heterogeneous disease, such as 'high-CRP inflammatory depression'). That kind of enrichment is the analytical bet most likely to surface a real signal in MDD. The all-comers approach forces brenipatide to show effect across a heterogeneous population where responder subgroups will be diluted by non-responders. Dosing is the other distinctive design feature. Brenipatide is once-monthly subcutaneous; tirzepatide and semaglutide are weekly [10][11]. In psychiatric and addiction indications where adherence is the central commercial problem, dosing interval matters as much as efficacy. The precedent is paliperidone palmitate versus oral risperidone in schizophrenia: the long-acting injectable form drove substantially better adherence and was priced and positioned accordingly. If brenipatide hits any of these endpoints, the monthly schedule is the feature that justifies premium pricing over weekly incretins and over cheap generic alternatives in the comparator field.

The model gives this drug a 20% chance of eventually being approved. That figure starts from the historical approval rate for Phase 3 drugs in this area, which is about 51%, then adjusts up or down based on ten facts about the trial and its sponsor. The estimate is helped by more secondary endpoints than usual and larger-than-typical enrollment, but held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The remaining facts fall close to average for this stage, leaving the final number well below the baseline.

Efficacy risk: MDD relapse-prevention trials place brenipatide on top of standard antidepressant care, so the comparison is incremental benefit over an already-treated patient. If placebo plus SOC relapses at 25 to 30% over the follow-up window, brenipatide needs to cut that meaningfully (say to 15 to 18%) to be commercially compelling. Without biomarker enrichment, dilution by non-responders is likely. Safety risk: Incretin-class drugs carry GI tolerability burden (nausea, vomiting, constipation), a suicidal ideation signal that the FDA reviewed and did not establish causally but continues to monitor, and pancreatitis labeling. The Wang et al. 2024 EHR analysis actually found reduced incident and recurrent suicidal ideation in semaglutide users versus matched controls on non-incretin anti-obesity or anti-diabetes drugs (HR ~0.27 and ~0.44 respectively), and EMA's pharmacovigilance committee found no causal link in its 2024 review [8]. That is reassuring as a class signal, but in a psychiatric population already at elevated suicide risk, any imbalance in self-harm events on the brenipatide arm could still derail the program even if the primary endpoint hits. GIP co-agonism does not carry the hepatic enzyme concerns that hepatic glucagon agonists do, but adds its own monitoring profile around insulin secretion and tolerability that is still being characterized as the class matures. Execution risk: Five concurrent Phase 2/3 trials across psychiatric and substance use indications is aggressive [1][2][3][4][5]. Site overlap, randomization competition, and patient pool dilution are real concerns in psychiatric trial networks that are already strained. Commercial risk: Even with a positive readout, payers will scrutinize a monthly injectable incretin add-on in MDD where generic SSRIs cost pennies per day. Brenipatide would need either an identifiable responder subgroup, a meaningful effect size, or a clear adherence advantage to justify reimbursement. The addiction indications offer cleaner commercial paths: smoking cessation is currently anchored by varenicline (Chantix) and bupropion, both generic and modestly effective; AUD is anchored by naltrexone and acamprosate, also generic and modestly effective. A monthly incretin with credible efficacy in either indication has a far cleaner pricing story than in MDD, where well-tolerated generics dominate.

Worth watching, but not for the MDD trial directly. The signal-rich reads are the addiction Phase 2/3 trials. Smoking cessation (NCT07223840, n=222) and the schizophrenia-associated weight Phase 2 (NCT07410507, n=450) will read first and will tell whether brenipatide is differentiated from semaglutide and tirzepatide in CNS-adjacent effects [2][3]. If brenipatide shows meaningful smoking cessation benefit beyond what semaglutide retrospective data already suggest, the MDD trial becomes more interesting. If it doesn't, MDD is a long shot regardless of design. Differentiation versus tirzepatide is the central thesis question. Brenipatide and tirzepatide target the same two receptors, share the same sponsor, and will compete for the same patient pool if both end up in psychiatric or addiction labels. Brenipatide's claim to differentiated value rests on two features: once-monthly dosing (adherence advantage in psychiatric populations) and a peptide structure engineered for longer half-life that may shift the pharmacokinetic profile. Tirzepatide already has real-world CNS observational data accumulating, and that data is the bar brenipatide must clear in prospective trials. What would make this a real signal: any Lilly disclosure of the brenipatide mechanism and full structure-activity profile. Until then, the asset is opaque on details a Phase 3 candidate would normally have published. Lilly has not released structure, binding affinity ratios, or selectivity data through peer-reviewed channels. The most likely venue for additional color is the next two Lilly earnings calls and the next Investor Day pipeline review. Connection to Lilly: Mounjaro and Zepbound generated combined $36.5 billion in FY2025 revenue ($23.0B Mounjaro, $13.5B Zepbound), making tirzepatide one of the top-selling prescription medicines in the world and Lilly the top pharma company by revenue at $65.2 billion total [12]. The next-generation incretin pipeline (retatrutide, orforglipron, brenipatide) is Lilly's core growth story [7]. Brenipatide extends the GIP/GLP-1 franchise into non-metabolic indications, the highest-margin direction if it works. Check back after the smoking cessation Phase 2 readout (plausible Q1 to Q2 2027), which is the earliest meaningful data drop.